Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cue Biopharma Inc V.CUE


Primary Symbol: CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.


NDAQ:CUE - Post by User

Post by nokiawatchon Dec 29, 2011 2:46pm
605 Views
Post# 19357547

Invest Now and Wait

Invest Now and Wait

 

Uranium - A Sector Powering Ahead

Prior to the tragic earthquake and tsunami in Japan the factors pushing uranium prices higher included the 443 reactors in operation worldwide and the 62 under construction. Today there are 432 nuclear reactors safety operating and 63 reactors are under construction.

In 2010, about 180 million pounds of uranium was consumed globally. However, only 130 million lbs was produced by uranium mines. This means that only 2/3 of uranium demand is being met by mine supply. The balance is made up for by secondary supplies like the US-Russian HEU Agreement. This agreement, which expires in 2013, supplies 13% of world's or 45% of U.S. annual uranium needs! This agreement still expires in 2013, while uranium consumption is expected to reach 230 MM lb per year by 2020.

There's simply not enough uranium coming from the world's mines right now to supply the current power plants across the world, let alone the next 63 under construction, and the further five hundred planned and proposed. Post Fukushima plans have been announced by the UK, US and Saudi Arabia to build new reactors whilst China, India and Russia, who represent 50% of new build, have all reaffirmed their support for Nuclear Energy.

Uranium stock prices are down and this presents a special investment opportunity.

 
<< Previous
Bullboard Posts
Next >>